MediWound Ltd. (NASDAQ:MDWD) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts' consensus: Five analysts give MediWound a consensus rating of "Hold" (1 sell, 1 hold, 3 buy) with an average 1‑year price target of $31.67, even as some firms recently downgraded the stock to "strong sell" or "sell".
• Weak fundamentals: The company reported Q results of ($0.56) EPS on $1.87M revenue, with a negative net margin (~-140.8%) and ROE (-65.79%), and sell‑side analysts forecast about -$2.75 EPS for the year.
• Market snapshot: MDWD trades near $16.57 with a ~$213M market cap and a 12‑month range of $14.90–$22.50, and roughly 46.8% of shares are held by hedge funds and institutional investors after recent small purchases.

MediWound Ltd. (NASDAQ:MDWD - Get Free Report) has been given a consensus rating of "Hold" by the five research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $31.6667.

Several equities research analysts have recently weighed in on MDWD shares. Wall Street Zen lowered MediWound from a "hold" rating to a "strong sell" rating in a research note on Saturday, March 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MediWound in a report on Tuesday, April 21st.

Institutional Trading of MediWound

A number of hedge funds have recently bought and sold shares of the company. Quarry LP purchased a new position in shares of MediWound in the fourth quarter worth approximately $26,000. BNP Paribas Financial Markets raised its holdings in shares of MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 723 shares during the period. Russell Investments Group Ltd. lifted its position in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 649 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock valued at $85,000 after acquiring an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in MediWound in the 4th quarter worth approximately $109,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Price Performance

MDWD stock opened at $16.57 on Tuesday. MediWound has a 12 month low of $14.90 and a 12 month high of $22.50. The firm has a market cap of $212.96 million, a PE ratio of -7.89 and a beta of 0.15. The firm has a 50 day simple moving average of $17.06 and a 200 day simple moving average of $17.76.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The business had revenue of $1.87 million during the quarter. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%. As a group, sell-side analysts expect that MediWound will post -2.75 earnings per share for the current year.

MediWound Company Profile

MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.